Kleinberg Kaplan Partner Marc Rosen Quoted on the Valeant-Pershing Square Settlement and the Takeaways for Activist Investors
Kleinberg Kaplan Litigation chair Marc Rosen was quoted extensively by the Hedge Fund Law Report concerning the announcement, on December 29, 2017, that Valeant Pharmaceuticals and Pershing Square have agreed to settle litigation against them alleging insider trading under SEC Rule 14e-3, in connection with the Alergan tender offer. Mr. Rosen discusses the genesis of…